Stock Scorer

Acro Biomedical Co., Ltd. (ACBM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 250K 500K 750K Q3 '21: 0 Q4 '21: 598K Q1 '22: 298.5K Q2 '22: 0 Q3 '22: 0 Q4 '22: 360K Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 60K 120K 180K Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 12.1K Q1 '20: 159.4K Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 29.5K Q2 '21: 80K Q3 '21: 0 Q4 '21: 150K Q1 '22: 76.5K Q2 '22: 0 Q3 '22: 0 Q4 '22: 64K Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -3M Q4 '21: -3.9M Q1 '22: -3.9M Q2 '22: -4M Q3 '22: -4M Q4 '22: -3.9M Q1 '23: -4M Q2 '23: -3.2M Q3 '23: -1.6M Q4 '23: -17.4K Q1 '24: -10.3K Q2 '24: -9.1K Q3 '24: -9.1K Q4 '24: -9.5K Q1 '25: -8.9K Q2 '25: -13.6K Q3 '25: -115.1K Q4 '25: -16.4K Q1 '26: -60.3K Q2 '26: -17.6K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -3M Q4 '21: -3.9M Q1 '22: -3.9M Q2 '22: -4M Q3 '22: -4M Q4 '22: -3.9M Q1 '23: -4M Q2 '23: -3.2M Q3 '23: -1.6M Q4 '23: -18.2K Q1 '24: -11.3K Q2 '24: -10.1K Q3 '24: -10.2K Q4 '24: -10.7K Q1 '25: -10.3K Q2 '25: -15.6K Q3 '25: -117.8K Q4 '25: 42.5K Q1 '26: -43.8K Q2 '26: -21.4K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 200K 400K 600K Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 181.4K Q1 '20: 528.6K Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 70K Q2 '21: 420K Q3 '21: 0 Q4 '21: 448K Q1 '22: 222K Q2 '22: 0 Q3 '22: 0 Q4 '22: 296K Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Cash Flow Quarterly

-450K -300K -150K 0 150K 300K 450K Q3 '21: -64.5K Q4 '21: -60.5K Q1 '22: 262.1K Q2 '22: -345.8K Q3 '22: -53.3K Q4 '22: -10.6K Q1 '23: -5.6K Q2 '23: 2.2K Q3 '23: 483 Q4 '23: -12.6K Q1 '24: -13.5K Q2 '24: -6.3K Q3 '24: -6.3K Q4 '24: -10.5K Q1 '25: -22.5K Q2 '25: -94K Q3 '25: -54.4K Q4 '25: -25.4K Q1 '26: -49.8K Q2 '26: -10.5K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Shares Outstanding Quarterly

0 25M 50M 75M Q3 '22: 60M Q1 '23: 60M Q2 '23: 60M Q3 '23: 60M Q1 '24: 60M Q2 '24: 60M Q3 '24: 60M Q1 '25: 60M Q2 '25: 60M Q3 '25: 60M Q1 '26: 60M Q2 '26: 60M Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.27 -0.18 -0.09 0.00 0.09 0.18 0.27 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: -0.02 Q3 '21: -0.07 Q4 '21: -0.14 Q2 '23: -0.25 Q3 '23: -0.21 Q4 '23: -0.15 Q1 '24: -0.08 Q2 '24: -0.03 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.00 Q2 '25: 0.00 Q3 '25: 0.00 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q3 '20 Q2 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ACBM: Free Cash Flow. Nothing in this filer's XBRL supports it for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.